Business, GlaxoSmithKline, Pharmaceuticals industry, UK news, Drugs, Financial sector, Stock markets Business | The Guardian
Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmedFinancial forecasts raised for a second time this year; share price still becalmed. If she didn’t have last year’s bumper £12.7m pay package to cushion the blow, one could sympathise with Emma Walmsley, chief executive at GlaxoSmithKline.The multi-year overhaul of the pharmaceutical firm on her watch seems finally to be delivering the operational goods but the share price, down 2% at £15.12 after Wednesday’s half-year figures, is stuck roughly in the middle of the £13-£18 range that has been GSK’s lot for the past decade. The main explanation is that, every time a break-out looks to be in prospect, something crops up. Continue reading…
Emma Walmsley’s overhaul seems to be delivering the goods even if US worries have left the share price becalmed
Financial forecasts raised for a second time this year; share price still becalmed. If she didn’t have last year’s bumper £12.7m pay package to cushion the blow, one could sympathise with Emma Walmsley, chief executive at GlaxoSmithKline.
The multi-year overhaul of the pharmaceutical firm on her watch seems finally to be delivering the operational goods but the share price, down 2% at £15.12 after Wednesday’s half-year figures, is stuck roughly in the middle of the £13-£18 range that has been GSK’s lot for the past decade. The main explanation is that, every time a break-out looks to be in prospect, something crops up.
